Abstract
Augmentation of antitumour activity of defucosylated chimeric anti‐CCR4 monoclonal antibody in SCID mouse model of adult T‐cell leukaemia/lymphoma using G‐CSF
Highlights
We explored the mechanisms whereby human G-CSF augments the anti-ATLL activity of KM2760 in vivo
Monocytes/macrophages were prepared from peritoneal exudate cells of 14 SCID mice receiving 10 lg G-CSF twice or 15 naıve SCID mice
The cells were stained with phycoerythrin cyanin 5 (PECy5)-conjugated anti-F4/80 mAb (Serotec Ltd, Oxford, UK), which binds mouse monocytes/macrophages, and analysed by BD FACSCalibur Flow Cytometer (BD Biosciences, San Jose, CA, USA) as previously described (Ishida et al, 2006)
Summary
We explored the mechanisms whereby human G-CSF augments the anti-ATLL activity of KM2760 in vivo. Monocytes/macrophages were prepared from peritoneal exudate cells of 14 SCID mice receiving 10 lg G-CSF twice (at 20 h and 5 h before testing) or 15 naıve SCID mice. As S-YU does not express CD20, rituximab (Chugai Pharmaceutical Co., Ltd, Tokyo, Japan) was used as a control mAb for KM2760.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
